Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of Directors

    NEXT STORY
    Sedation In ICU Setting Market to reach US$ 3688.2 Mn by 2026, exhibiting a CAGR of 5.7%. | Fortune Business Insights
    PREV STORY
    Evelo Biosciences Secures $45 Million Debt Financing from K2 HealthVentures
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    TRACON Pharmaceuticals Announces Filing of Protocol for ENVASARC Pivotal Trial with the FDA

    author_avatar
    NASDAQ Market News

    Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer

    Dr. Mark Murray, Arbutus President & Chief Executive Officer, to participate in a fireside ...

    author_avatar
    NASDAQ Market News

    Castle Creek Pharmaceutical Holdings to Acquire Fibrocell

    author_avatar
    NASDAQ Market News